<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bao B</submitter><funding>Medical and Health Science and Technology Program of Zhejiang Province</funding><pagination>e70020</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11549061</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>18(11)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Kinesin family member 5A (KIF5A) has been reported to be closely related to cancer progression. The aim of this study was to investigate the effect of KIF5A on lung adenocarcinoma (LUAD) and its potential molecular mechanisms.&lt;h4>Methods&lt;/h4>Using bioinformatics analysis methods and molecular experiments, the expression of KIF5A in LUAD was analyzed, with its expression in attached and detached tumor cells assessed. Gene set enrichment analysis (GSEA) of KIF5A was carried out. The small molecular drug with the highest affinity for KIF5A was screened out through molecular docking experiments, which was validated through cellular thermal shift assay (CETSA). Quantitative polymerase chain reaction (qPCR) was employed to measure the expression levels of anoikis-repressing ge</pubmed_abstract><journal>The clinical respiratory journal</journal><pubmed_title>Ergotamine Targets KIF5A to Facilitate Anoikis in Lung Adenocarcinoma.</pubmed_title><pmcid>PMC11549061</pmcid><funding_grant_id>2024KY265</funding_grant_id><pubmed_authors>Zheng W</pubmed_authors><pubmed_authors>Bao B</pubmed_authors><pubmed_authors>Yu X</pubmed_authors><pubmed_authors>Sun J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Ergotamine Targets KIF5A to Facilitate Anoikis in Lung Adenocarcinoma.</name><description>&lt;h4>Background&lt;/h4>Kinesin family member 5A (KIF5A) has been reported to be closely related to cancer progression. The aim of this study was to investigate the effect of KIF5A on lung adenocarcinoma (LUAD) and its potential molecular mechanisms.&lt;h4>Methods&lt;/h4>Using bioinformatics analysis methods and molecular experiments, the expression of KIF5A in LUAD was analyzed, with its expression in attached and detached tumor cells assessed. Gene set enrichment analysis (GSEA) of KIF5A was carried out. The small molecular drug with the highest affinity for KIF5A was screened out through molecular docking experiments, which was validated through cellular thermal shift assay (CETSA). Quantitative polymerase chain reaction (qPCR) was employed to measure the expression levels of anoikis-repressing ge</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Nov</publication><modification>2025-04-22T16:23:08.367Z</modification><creation>2025-04-06T01:44:34.696Z</creation></dates><accession>S-EPMC11549061</accession><cross_references><pubmed>39517115</pubmed><doi>10.1111/crj.70020</doi></cross_references></HashMap>